Middle East Midline Catheters Market (2025 - 2033)

Middle East Midline Catheters Market Summary

The Middle East midline catheters market size was estimated at USD 78.38 million in 2024 and is projected to reach USD 119.76 million by 2033, growing at a CAGR of 4.81% from 2025 to 2033. The regional industry is growing due to healthcare modernization, rising chronic disease rates, and demand for cost-effective vascular access.

Investments in infrastructure, especially in Saudi Arabia and the UAE, under initiatives like Vision 2030, are driving adoption. Increased cases of diabetes, cancer, and cardiovascular diseases requiring long-term IV therapy further fuel the demand. The shift toward outpatient and home care, along with innovations such as ultrasound-guided insertion and antimicrobial coatings, enhances safety and supports wider use of midline catheters.

The rising preference for minimally invasive procedures is driving the adoption of midline catheters in the Middle East, as they provide a safer, less invasive alternative to central lines for intermediate-term IV therapy. Reducing risks such as bloodstream infections and supporting faster recovery aligns with growing trends toward patient-centered and cost-effective care. For instance, in June 2023, the Saudi Journal of Emergency Medicine published a study showing that simulation-based training significantly improved emergency physicians’ and nurses’ skills and confidence in ultrasound-guided midline catheter insertion, highlighting the importance of hands-on education in enhancing procedural proficiency.

The rising prevalence of diabetes is a key factor driving the growth of the midline catheter market in the Middle East. Diabetic patients often require frequent and prolonged intravenous therapies for managing infections, administering medications, or maintaining hydration-needs that are well-suited for midline catheters. These devices offer a safer and more efficient alternative to repeated peripheral IV insertions, reducing vein damage and infection risks. As diabetes continues to burden regional healthcare systems significantly, the demand for reliable, long-term vascular access solutions like midline catheters is expected to grow.

Diabetes Cases 2024

Source: IDF

Market Concentration & Characteristics

The industry in the Middle East is significantly growing, driven by rising demand for safe, intermediate-term IV access and substantial healthcare investments, especially in GCC countries such as Saudi Arabia, UAE and Qatar. Key characteristics include a focus on infection control, increasing adoption of advanced catheter technologies, and support from government healthcare reforms like Saudi Vision 2030. While urban centers lead in adoption and training, rural areas still face access gaps. The market is also shifting toward local production, standardization, and enhanced clinical training to support long-term growth.

The Middle East midline catheter industry shows moderate to high innovation, driven by advances in catheter materials, design, and insertion techniques like ultrasound guidance. Rising awareness of infection control, patient comfort, and the shift toward minimally invasive procedures support this progress. Emerging features such as antimicrobial coating reflect a dynamic market focused on improving vascular access outcomes. For instance, in March 2025, the NIH reported increased adoption of midline catheters for IV therapy in patients needing intermediate-term vascular access. This shift aims to improve outcomes, reduce complications from peripheral IVs and central lines, and enhance efficiency in care settings. Midline catheters, inserted in the upper arm to the axillary vein, offer a safe, cost-effective option for 1-4 week therapies while addressing CLABSI risks and patient comfort.

Regulatory frameworks in the Middle East significantly shape the market by influencing product approvals, safety standards, and market access. Stricter regulations on infection control and device safety have driven innovation in catheter design and insertion techniques. Alignment with international standards, like FDA and CE, supports cross-border trade, though regional regulatory differences require localized strategies. For example, in January 2023, Saudi Arabia’s Ministry of Health issued updated catheter-associated urinary tract infections (CAUTI) prevention guidelines to standardize catheter use, promote aseptic techniques, and ensure timely removal. The initiative aimed to reduce infection rates, improve patient safety, and align with global best practices.

M&A activities in the Middle East midline catheters market remain limited, but gradually grow alongside broader healthcare sector consolidation. Driven by Saudi Arabia's Vision 2030, international firms are forming partnerships and exploring local opportunities to meet rising demand, improve supply chains, and expand market presence in advanced vascular access solutions. Increased government support for healthcare modernization and growing emphasis on medical device innovation are expected to boost M&A momentum in this sector further. As the market matures, strategic acquisitions will accelerate growth and enhance competitive advantage.

Several product substitutes exist in the region, depending on clinical needs and therapy duration. These include peripheral intravenous (PIV) catheters for short-term use, peripherally inserted central catheters (PICCs) for longer therapies, and central venous catheters (CVCs) for critical care requiring high flow rates. Other alternatives include implantable ports for long-term intermittent access, tunneled catheters for chronic conditions like dialysis, and subcutaneous infusion devices used mainly in palliative care. While midline catheters bridge the gap between short-term and central access, the choice of substitute depends on factors such as patient condition, infection risk, cost, and healthcare infrastructure.

The regional expansion is gaining momentum, driven by growing healthcare investments, increasing demand for minimally invasive procedures, and a rising focus on infection control. Countries such as Saudi Arabia, the UAE, and Qatar are leading this growth, supported by national healthcare reforms and modernization efforts. As hospitals and outpatient clinics expand their services, midline catheters are being increasingly adopted for intermediate-term therapies, offering a safer and more cost-effective alternative to central lines. The market also benefits from greater awareness among healthcare professionals, improved training, and the gradual localization of medical device manufacturing across the region.

Design Insights

The single lumen segment dominates the midline catheter market in the Middle East due to its widespread clinical acceptance, cost-effectiveness, and lower risk of complications. These catheters are commonly preferred for short- to medium-term intravenous therapies such as antibiotics, hydration, and medications where a single infusion line suffices. Their simpler design reduces insertion complexity and maintenance, making them the preferred choice in many inpatient and outpatient settings across the region. Additionally, healthcare providers favor single lumen devices for their lower infection risk, further strengthening their market position in the Middle East.

The double-lumen midline catheter segment is expected to register the fastest CAGR during the forecast period in the Middle East, driven by rising demand for complex and simultaneous infusion therapies. These catheters enable the administration of incompatible drugs or fluids without multiple insertion sites, enhancing patient comfort and treatment efficiency, particularly in critical care and oncology settings. As hospitals and infusion centers adopt advanced care protocols and aim to reduce catheter-related complications, using double-lumen catheters for managing multi-therapy regimens is becoming increasingly important, fueling rapid market growth.

Product Type Insights

Midline catheters dominate the Middle East as a safer, cost-effective alternative to central venous catheters for intermediate intravenous therapies. Inserted in the upper arm, they carry fewer risks like infections and thrombosis and are widely used in hospitals and outpatient settings for administering medications. Their safe use for 2-4 weeks without complications further drives their regional popularity. For instance, in November 2024, a cross-sectional study in Saudi Arabia examined central venous catheter insertion profiles and associated complications among neonates. The study highlighted key risks like infections and thrombosis, emphasizing the need for careful catheter management. These findings underscore the potential benefits of safer alternatives like midline catheters, which offer a less invasive option with a lower risk of serious complications, making them a promising choice for intermediate-term vascular access in neonatal care.

The midline catheter kit segment in the Middle East is expected to experience the fastest CAGR during the forecast period, spurred by rising demand for ready-to-use, sterile, and comprehensive solutions that simplify the insertion process. These kits, typically containing the catheter, introducer needle, guidewire, and other essential components, help reduce preparation time, minimize infection risks, and improve procedural efficiency. Hospitals and outpatient clinics across the region increasingly prefer all-in-one kits to enhance patient care and comply with infection control standards. Additionally, advancements in kit design and growing awareness of midline catheter benefits among healthcare professionals are fueling the robust growth of this segment in the Middle East.

Material Insights

The polyurethane segment spearheads the market in the Middle East, holding the largest share due to its ideal balance of strength, flexibility, and biocompatibility. Its superior kink resistance and tensile strength make it well-suited for maintaining catheter integrity during extended use. Polyurethane catheters are more straightforward to insert and durable, reducing breakage or dislodgement risks. In addition, their compatibility with power injection for contrast-enhanced imaging boosts their adoption in hospitals and outpatient facilities across the region. These advantages make polyurethane the preferred choice among clinicians, reinforcing its market dominance in the Middle East. For instance, in November 2023, Argon Medical Devices introduced their L-Cath PICC and Midline Catheters, designed for safe and easy placement. Made from polyurethane, these catheters enhance strength and increase flow rates, offering reliable and efficient vascular access solutions.

The silicone segment is expected to grow significantly in the Middle East due to its superior biocompatibility and softness, which is ideal for long-term vascular access. The flexible and atraumatic design reduces irritation and vein trauma, enhancing patient comfort and lowering the risk of thrombophlebitis. Silicone catheters are particularly beneficial for sensitive groups such as pediatric, geriatric, and oncology patients. With a growing emphasis on patient-centered care and long-term safety among healthcare providers in the region, demand for silicone-based midline catheters is set to rise, driving market growth.

End Use insights

The hospital segment dominates the industry due to its extensive infrastructure and high patient volume requiring vascular access for treatments such as prolonged antibiotic therapy, hydration, and medication administration. Specialized departments like oncology, intensive care, and surgery further drive demand for reliable and safe vascular access devices. Hospitals also have trained staff and resources to insert and manage midline catheters effectively, reinforcing their leading role in the market. The critical care needs and inpatient treatment protocols ensure consistent and significant use of midline catheters in hospital settings.

The Ambulatory Surgical Centers (ASCs) segment is expected to experience the fastest growth over the forecast period. This is driven by a rising preference for outpatient procedures and minimally invasive surgeries in the region. ASCs provide cost-effective and convenient healthcare for short-term treatments requiring vascular access, such as chemotherapy and intravenous therapies. Advances in medical technology, supportive reimbursement policies, and increasing patient demand for quicker recovery are key factors fueling this growth. As the number of ASCs in the Middle East expands, midline catheter adoption in these settings is expected to rise significantly.

Country Insights

UAE Midline Catheters Market Trends

The UAE midline catheter industry is growing, driven by expanding healthcare infrastructure, rising demand for intermediate-term vascular access, and a focus on infection control. Hospitals, especially oncology and critical care, are the main users, valuing midline catheters as safer, cost-effective alternatives to central lines. Technological advancements and increased awareness among healthcare professionals are boosting adoption, particularly among adult and elderly patients. For instance, in July 2024, Emirates Health Services announced that Al Qassimi Hospital in Sharjah acquired the region’s first cardiac catheterization simulator from HeartRoid, featuring three specialized models for coronary artery interventions, aortic valve replacement, and cardiac electrophysiology. This advanced simulator enhances interventional cardiology training through realistic, hands-on practice, improving physician skills and patient safety while supporting the UAE’s commitment to healthcare innovation.

Qatar Midline Catheters Market Trends

The Qatar midline catheter industry is growing, driven by healthcare investments, rising chronic diseases, an aging population, and increasing demand for safer, intermediate-term vascular access. Advances like ultrasound-guided insertion and enhanced infection control are boosting adoption in hospitals and outpatient settings. For instance, in March 2025, Qatar Charity launched a project in Yemen’s Taiz Governorate to treat heart patients needing intravenous therapies, including midline catheter use, aiming to support more. Qatari donations fund the initiative and highlight the nation’s commitment to improving healthcare access with advanced medical solutions.

Key Middle East Midline Catheters Company Insights

Leading companies in the market play a crucial role by driving innovation, developing new products, and forming strategic alliances. These key players work to expand their presence in the region, improve catheter design, and enhance safety features to increase their market share. Through investments in research and robust distribution channels, they effectively address rising demand in healthcare, fueling competition and influencing the market’s growth direction.

Recent Development

• In March 2025, Qatar Charity launched a project in Yemen’s Taiz Governorate to treat 70 heart patients needing intravenous therapies, including midline catheter use, aiming to support 180 more. Qatari donations fund the initiative and highlight the nation’s commitment to improving healthcare access with advanced medical solutions.

• In December 2024, the WHO recognized Saudi Arabia for significantly reducing central line-associated bloodstream infections (CLABSIs), with a 48.8% annual decrease between 2021 and 2024. This achievement, driven by the Ministry of Health’s 2022 national strategy, highlights the country’s strong focus on infection control. As a result, there is growing interest in safer vascular access alternatives like midline catheters, which carry lower infection risks. This shift supports the rising adoption of midline catheters across the Middle East as part of broader efforts to improve patient safety and meet Vision 2030 healthcare goals.

• In July 2024, Emirates Health Services announced that Al Qassimi Hospital in Sharjah acquired the region’s first cardiac catheterization simulator from HeartRoid, featuring three specialized models for coronary artery interventions, aortic valve replacement, and cardiac electrophysiology. This advanced simulator enhances interventional cardiology training through realistic, hands-on practice, improving physician skills and patient safety while supporting the UAE’s commitment to healthcare innovation.

• In June 2022, Teleflex launched its new Arrow Pressure Injectable Midline Catheter across the Europe, Middle East, and Africa (EMEA) region. This advanced catheter is designed for pressure injection of contrast media and extended dwell times, offering improved performance, safety, and patient comfort. Its introduction marks a significant development in the Middle East midline catheter market, providing healthcare providers with a reliable and efficient option for intermediate-term intravenous therapies. The launch aligns with the region’s growing demand for innovative vascular access solutions that support infection control and clinical efficiency.

Middle East Midline Catheters Market